Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) – Investment analysts at Wedbush reduced their Q3 2017 EPS estimates for shares of Verona Pharma PLC American Depositary Share in a note issued to investors on Monday. Wedbush analyst L. Moussatos now expects that the company will post earnings of ($0.42) per share for the quarter, down from their previous estimate of ($0.38). Wedbush has a “Outperform” rating and a $25.00 price objective on the stock. Wedbush also issued estimates for Verona Pharma PLC American Depositary Share’s Q4 2017 earnings at ($0.43) EPS, FY2017 earnings at ($1.62) EPS, Q1 2018 earnings at ($0.44) EPS, Q2 2018 earnings at ($0.46) EPS, Q3 2018 earnings at ($0.48) EPS, Q4 2018 earnings at ($0.50) EPS, FY2018 earnings at ($2.15) EPS, FY2019 earnings at ($2.52) EPS, FY2020 earnings at ($2.93) EPS and FY2021 earnings at ($3.32) EPS.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09.

TRADEMARK VIOLATION WARNING: “Q3 2017 EPS Estimates for Verona Pharma PLC American Depositary Share Reduced by Wedbush (VRNA)” was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://theolympiareport.com/2017/08/17/q3-2017-eps-estimates-for-verona-pharma-plc-american-depositary-share-reduced-by-wedbush-vrna.html.

Several other equities research analysts have also issued reports on VRNA. Stifel Nicolaus started coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $22.00 target price for the company. SunTrust Banks, Inc. started coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $26.00 target price for the company. Jefferies Group LLC reissued a “buy” rating and issued a $26.00 target price on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Finally, Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a report on Tuesday, July 25th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $22.60.

Shares of Verona Pharma PLC American Depositary Share (VRNA) opened at 12.2702 on Wednesday. The company’s 50-day moving average is $14.21 and its 200-day moving average is $13.74. Verona Pharma PLC American Depositary Share has a 12-month low of $11.03 and a 12-month high of $17.50. The stock’s market cap is $78.77 million.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. FIL Ltd acquired a new position in Verona Pharma PLC American Depositary Share during the second quarter valued at $873,000. Tekla Capital Management LLC acquired a new position in Verona Pharma PLC American Depositary Share during the second quarter valued at $3,211,000. Finally, Vivo Capital LLC acquired a new position in Verona Pharma PLC American Depositary Share during the second quarter valued at $8,208,000. Institutional investors and hedge funds own 10.46% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Earnings History and Estimates for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with Analyst Ratings Network's FREE daily email newsletter.